EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Associations of TACSTD2 / TROP2 and NECTIN‐4 / NECTIN ‐4 with molecular subtypes, PD‐L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts

Veronika Bahlinger iD, Annalena Branz, Pamela L Strissel, Reiner Strick, Fabienne Lange, Carol I Geppert, Niklas Klümper, Michael Hölzel, Sven Wach, Helge Taubert, Danijel Sikic, Bernd Wullich und 8 weitere

Histopathology · 2024

DOI: 10.1111/his.15130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Histopathology, 2024. Verfasst von Veronika Bahlinger und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences, Deutsche Forschungsgemeinschaft (DFG, German Research Foundation).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims Treatment options for advanced urothelial carcinoma (aUC) rapidly evolved: besides immunomodulative therapeutic options and inhibitors targeting Fibroblast growth factor receptor (FGFR) alterations, two new antibody‐drug conjugates (ADC), sacituzumab govitecan (SG) and enfortumab vedotin (EV), have been approved. However, little is known about the associations of specific aUC properties and the surface target expression of TROP2 and NECTIN‐4. Our aim was to characterize associations of TACSTD2 /TROP2 and NECTIN‐4 /NECTIN‐4 protein and gene expression with morphomolecular and clinicopathological characteristics of aUC in two large independent cohorts. Methods and results The TCGA BLCA ( n = 405) and the CCC‐EMN ( n = 247) cohorts were retrospectively analysed. TROP2/ TACSTD2 and NECTIN‐4/ NECTIN‐4 are highly expressed at the protein and transcript level in aUC, and their expression status did not correlate with patient survival in both cohorts. NECTIN‐4/ NECTIN‐4 expression was higher in luminal tumours and reduced in squamous aUCs. NECTIN‐4 was negative in 10.6% of samples, and 18.4% of samples had low expression ( H ‐score

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCarcinoma, Transitional CellHumansNectinsB7-H1 AntigenRetrospective StudiesCell Adhesion MoleculesAntigens, NeoplasmReceptor, Fibroblast Growth Factor, Type 3

Stichwörter der Autor:innen

Advanced urothelial carcinomaNECTIN-4/NECTIN-4TACSTD2/TROP2membranous expressiontreatment options

Substanzen

NectinsB7-H1 AntigenCell Adhesion MoleculesTACSTD2 protein, humanAntigens, NeoplasmFGFR3 protein, humanReceptor, Fibroblast Growth Factor, Type 3

Autor:innen und Institutionen

  • Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Bayerisches Zentrum für Krebsforschung (BZKF), Site University Hospital Erlangen, Erlangen, Germany.
  • Laboratory for Molecular Medicine, Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
  • Department of Urology, University Medical Center Bonn (UKB), Bonn, Germany.
  • Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany.

ORCID-Profile: Veronika Bahlinger, Miriam Angeloni, Fulvia Ferrazzi

Förderung

  • Gilead Sciences
  • Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)

Zitieren

APA

Bahlinger, V., Branz, A., Strissel, P. L., Strick, R., Lange, F., Geppert, C. I., Klümper, N., Hölzel, M., Wach, S., Taubert, H., Sikic, D., Wullich, B., Angeloni, M., Ferrazzi, F., Diehl, L., Kovalenko, M., Elboudwarej, E., Jürgensmeier, J. M., Hartmann, A., & Eckstein, M. (2024). Associations of TACSTD2 / TROP2 and NECTIN‐4 / NECTIN ‐4 with molecular subtypes, PD‐L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts. Histopathology. https://doi.org/10.1111/his.15130

Vancouver

Bahlinger V, Branz A, Strissel PL, Strick R, Lange F, Geppert CI, et al. Associations of TACSTD2 / TROP2 and NECTIN‐4 / NECTIN ‐4 with molecular subtypes, PD‐L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts. Histopathology. 2024. doi:10.1111/his.15130

BibTeX
@article{Bahlinger2024,
  author = {Bahlinger, Veronika and Branz, Annalena and Strissel, Pamela L and Strick, Reiner and Lange, Fabienne and Geppert, Carol I and Klümper, Niklas and Hölzel, Michael and Wach, Sven and Taubert, Helge and Sikic, Danijel and Wullich, Bernd and Angeloni, Miriam and Ferrazzi, Fulvia and Diehl, Lauri and Kovalenko, Maria and Elboudwarej, Emon and Jürgensmeier, Juliane M and Hartmann, Arndt and Eckstein, Markus},
  title = {Associations of TACSTD2 / TROP2 and NECTIN‐4 / NECTIN ‐4 with molecular subtypes, PD‐L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts},
  journal = {Histopathology},
  year = {2024},
  doi = {10.1111/his.15130}
}
Kostenlos starten →